[儿科药物的营销] - Suppr

Suppr

超能文献

[Marketing of pediatric drugs].

作者信息

Pabst Jean-Yves

机构信息

Université Louis-Pasteur, Faculté de pharmacie, Illkirch (67).

出版信息

Soins Pediatr Pueric. 2003 Jan-Feb(210):18-9.

PMID:12683130

Abstract

摘要

相似文献

[Marketing of pediatric drugs].

Soins Pediatr Pueric. 2003 Jan-Feb(210):18-9.

[European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].

Lakartidningen. 2003 Oct 30;100(44):3541-2.

[Europe for the development of pediatric drugs].

Soins Pediatr Pueric. 2002 Jun(206):5-6.

[New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].

Ugeskr Laeger. 2003 Apr 14;165(16):1648-9.

[Marketing authorization for pharmaceuticals: the necessity of European collaboration].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jul;51(7):703-4. doi: 10.1007/s00103-008-0593-7.

Positioning, labelling and control of medical information: artesunate strategy and Arsumax development story.

Med Trop (Mars). 1998;58(3 Suppl):70-2.

Getting SMART (submission management and review tracking) drug review in the computer age.

FDA Consum. 1995 Oct;29(8):6-9.

Data protection: an anti-generic weapon.

Prescrire Int. 2003 Dec;12(68):235.

[Orphan drugs: some legal, ethical and economics aspects].

Rev Epidemiol Sante Publique. 2001 Sep;49(4):387-96.

Fractured European market undermines biosimilar launches.

Nat Biotechnol. 2008 Jan;26(1):5-6. doi: 10.1038/nbt0108-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Marketing of pediatric drugs].

作者信息

Pabst Jean-Yves

机构信息

Université Louis-Pasteur, Faculté de pharmacie, Illkirch (67).

出版信息

Soins Pediatr Pueric. 2003 Jan-Feb(210):18-9.

PMID:12683130

Abstract

摘要

相似文献

[Marketing of pediatric drugs].

Soins Pediatr Pueric. 2003 Jan-Feb(210):18-9.

[European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].

Lakartidningen. 2003 Oct 30;100(44):3541-2.

[Europe for the development of pediatric drugs].

Soins Pediatr Pueric. 2002 Jun(206):5-6.

[New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].

Ugeskr Laeger. 2003 Apr 14;165(16):1648-9.

[Marketing authorization for pharmaceuticals: the necessity of European collaboration].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jul;51(7):703-4. doi: 10.1007/s00103-008-0593-7.

Positioning, labelling and control of medical information: artesunate strategy and Arsumax development story.

Med Trop (Mars). 1998;58(3 Suppl):70-2.

Getting SMART (submission management and review tracking) drug review in the computer age.

FDA Consum. 1995 Oct;29(8):6-9.

Data protection: an anti-generic weapon.

Prescrire Int. 2003 Dec;12(68):235.

[Orphan drugs: some legal, ethical and economics aspects].

Rev Epidemiol Sante Publique. 2001 Sep;49(4):387-96.

Fractured European market undermines biosimilar launches.

Nat Biotechnol. 2008 Jan;26(1):5-6. doi: 10.1038/nbt0108-5.